Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infective drugs aimed at addressing the global crisis of multidrug-resistant pathogens, thereby significantly improving the lives of people worldwide affected by severe and life-threatening diseases. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem-class anti-infective compound in Phase 3 clinical development, with both oral and intravenous formulations. Sulopenem has demonstrated in vitro effectiveness against a variety of Gram-negative, Gram-positive, and anaerobic bacteria that are resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and intravenous sulopenem formulations across seven indications.